Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 12,500 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $32.17, for a total transaction of $402,125.00. Following the sale, the chief executive officer now owns 441,417 shares of the company’s […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $33.70, for a total value of $421,250.00. Following the completion of the sale, the chief executive officer now owns 441,417 shares of […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price […]
JMP Securities reissued their market outperform rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $71.00 price objective on the biopharmaceutical company’s stock. CYTK has been the topic of several other reports. HC Wainwright reiterated a buy rating and set a […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) shares saw unusually-high trading volume on Tuesday after Cantor Fitzgerald raised their price target on the stock from $59.00 to $65.00. Cantor Fitzgerald currently has an overweight rating on the stock. Approximately 2,088,646 shares changed hands during mid-day trading, an increase of 127% from the previous session’s volume […]